Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Resource type
Journal Article
Authors/contributors
- Russo, Domenico (Author)
- Schmitt, Michael (Author)
- Pilorge, Sylvain (Author)
- Stelljes, Matthias (Author)
- Kawakita, Toshiro (Author)
- Teal, Valerie L. (Author)
- Haber, Barbara (Author)
- Bopp, Charlene (Author)
- Dadwal, Sanjeet S. (Author)
- Badshah, Cyrus (Author)
Title
Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Publication
The Lancet Haematology
Volume
11
Issue
2
Pages
e127-e135
Date
2024-02-01
Journal Abbr
The Lancet Haematology
Language
English
ISSN
2352-3026
Short Title
Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection
Accessed
5/19/24, 8:51 AM
Library Catalog
Extra
Publisher: Elsevier
PMID: 38142695
Citation
Russo, D., Schmitt, M., Pilorge, S., Stelljes, M., Kawakita, T., Teal, V. L., Haber, B., Bopp, C., Dadwal, S. S., & Badshah, C. (2024). Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Haematology, 11(2), e127–e135. https://doi.org/10.1016/S2352-3026(23)00344-7
ORGANISMS
HEME-ONC AND CELLULAR THERAPIES
Link to this record